Company intelligence / Profile preview

Reflexion Partners

Hayward, California, United Statesreflexionpartners.com ↗

Ownership: Private
Employees: ~201
Development stage: Other

Overview

First-in-human treatments completed at Stanford Medicine Cancer Center with SCINTIX therapy. FDA De Novo marketing authorization granted for lung/bone indications. Real-world outcomes registry launched.

Therapeutic areas: Oncology
Modalities: Radiopharmaceutical-directed therapy (SCINTIX)External-beam radiotherapy (SRS, SBRT, IMRT)Device-based therapy (Radiotherapy platform)
Industry: Therapeutic Medical Devices

Partnerships

Partnership with biotechnology provider 3B Pharmaceuticals to expand treatable patient population using its SCINTIX system

Beyond the preview

Go deeper on Reflexion Partners.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Reflexion Partners.

Explore the full profile